Navigation Links
Reportlinker Adds Global Antibiotics Industry
Date:11/16/2010

NEW YORK, Nov. 16, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Antibiotics Industry

http://www.reportlinker.com/p092489/Global-Antibiotics-Industry.html

This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTIBIOTICS MCP-1705

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 2

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

Penicillin 4

Cephalosporins 4

Macrolides 4

Quinolones 4

Carbapenems 4

Other Antibiotics 5

Aminoglycosides 5

Tetracyclines 5

Sulfonamides 5

Mupirocin 5

Glycopeptides 5

Synercid 6

Oxazolidinones 6

Linezolid 6

2. INDUSTRY OVERVIEW 7

Antibiotic Resistance and Generic Competition to Impact Long

Term Growth 7

New Regulations Guiding Usage of Drugs to Drive Growth 7

Current & Future Analysis 7

3. MARKET DYNAMICS 9

Anti-Bacterials Segment Drives Global Anti- Infectives Market 9

Antibiotic Resistance - A Primary Growth Inhibitor 9

Antibiotic-Resistant Bacteria by Type 9

Patent Expiries Commoditize Antibiotics 10

Patent Expiries of Leading Drugs in the Recent Past, Current,

and Future (2000 -2013) 10

Anti-MRSA Antibiotics Find Their Way 10

Table 1: World MRSA Treatments (2007 & 2008) : Percentage

Share Breakdown by Leading Antibiotic Drugs -Vancomycin,

Zyvox, Cubicin and Tygacil (includes corresponding

Graph/Chart) 11

Key Antibiotics in Pipeline 11

4. COMPETITION 12

Highly Competitive Market 12

Table 2: Leading Players in the Worldwide Antibiotics Market

(2008): Percentage Breakdown by Value Sales for Pfizer, Glaxo

Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott,

Wyeth, and Others (includes corresponding Graph/Chart) 12

GlaxoSmithKline - The Undisputed Leader of Penicillin Market 13

Table 3: Worldwide Leading Antibiotics within Penicillin

Class (2005 & 2006): Percentage Breakdown by Value for

Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes

corresponding Graph/Chart) 13

GlaxoSmithKline Leads Cephalosporin Market 14

Table 4: Worldwide Leading Antibiotics within Cephalosporin

Class (2005 & 2006): Percentage Breakdown by Value for

Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil,

Cefzon, Flumarin, and Others (includes corresponding

Graph/Chart) 14

Pfizer Dominates Macrolides Market 15

Table 5: Worldwide Leading Antibiotics within Macrolide Class

(2005 & 2006): Percentage Breakdown by Value for Zithromax,

Klaricid/Biaxin, Ketek, and Others (includes corresponding

Graph/Chart) 15

Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic 16

Table 6: Worldwide Leading Antibiotics within Quinolone Class

(2005 & 2006): Percentage Breakdown by Value for

Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and

Others (includes corresponding Graph/Chart) 16

Merck Rules Carbapenems Market 17

Table 7: Worldwide Leading Antibiotics within Carbapenem

Class (2005 & 2006): Percentage Breakdown by Value for

Primaxin, Merrem, Invanz, and Others (includes corresponding

Graph/Chart) 17

5. PRODUCT OVERVIEW 18

Antibiotics - An Introduction 18

Antibiotic Resistance 18

b-Lactams 19

Classification of Antibiotics 20

Key Milestones in Antibiotic Development 20

Antibiotic Types 20

Penicillin 20

History 21

About the Drug 21

Cephalosporins 21

Treatment 22

Effects of the Drug 22

Macrolides 22

Treatment 23

Quinolones 23

Table 8: Leading Global Ciprofloxacin Brands: (2006-2008)

(includes corresponding Graph/Chart) 23

Carbapenems 24

Other Antibiotics 24

Aminoglycosides 24

Treatment 24

Effects of the Drug 24

Tetracyclines 25

Treatment 25

Effects of the Drug 26

Sulfonamides 26

Treatment 26

Effects of the Drug 27

Mupirocin 27

Glycopeptides 27

Synercid 27

Oxazolidinones 28

Linezolid 28

6. RESEARCH FINDINGS 29

New Design for Monitoring Toxin Delivery Activity of

Pathogenic Bacteria 29

Cephalosporins Effective when Compared to Penicillin 29

FDA Bans Baytril Antibiotic for Chickens 29

Erythromycin Along with Some Specific Drugs Increase Risk of

Sudden Death 29

Rise in Usage of Quinolones for Urinary Tract Infections Leads

to Drug Resistance 30

Polyphor Discovers POL7080 - New Antibiotic Against Gram-

Negative Bacteria 30

7. FDA APPROVALS/PATENTS 31

MiddleBrook Obtains NDA Approval for MOXATAG™ 31

J&JPRD Seeks FDA Approval for Doripenem Antibiotic 31

J&JPRD Seeks FDA Approval for Investigational Antibiotic,

Ceftobiprole 31

GSK Receives Approval for ALTARGO® in Europe 31

APL Receives FDA Approval for Cefpodoxime Proxetil 32

Cubist Receives Approval to Market CUBICIN in Canada 32

Cubist Obtains Approval to Market CUBICIN for Added

Indications in EU 32

Cubist Gains Approval for CUBICIN in Taiwan and South Korea 32

Cethromycin Achieves FDA's Orphan Drug Designation 32

FDA Approves Wockhardt's Cefotaxime Injection 33

FDA Approves Doxycycline Tablets 33

FDA Approves Clarithromycin 33

FDA Approves Doxycycline Tablets For The US Market 33

Johnson & Johnson Applies Doripenem For FDA Approval 33

FDA Certifies Antibioticos do Brasil's Plant 33

FDA Certifies ANDA For Cefdinir Capsules 34

US FDA Approves Teva's Cefprozil Tablets 34

FDA Certifies ANDA for Cephalexin Capsules 34

American Pharmaceutical Partners Receives FDA Approvals for

Ceftriaxone for Injection, USP 34

Advancis's Keflex Receives FDA Approval 34

Wockhardt Gains Marketing Approval for Cefuroxime axetil in

the US 34

Wyeth's Mylotarq Receives Government's Approval 35

FDA Approves Generic Version of Zithromax 35

Pfizer Wins FDA Approval for Zmax™ 35

Venus Remedies Files Second PCT for New Cephalosporins 36

Falcon Gains US FDA Approval for its Generic Anti-Infective

Solution 36

Cadilla Receives FDA Approval to Market Clindamycin 36

8. RECENT INDUSTRY ACTIVITY 37

DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the

Netherlands 37

Daiichi Leverages Ranbaxy's Network to Market Tavanic in South

Africa and Romania 37

Pfizer Acquires Wyeth 37

Durata Therapeutics Acquires Pfizer's Vicuron Pharmaceuticals 37

Cubist Completes Acquisition of Calixa Therapeutics 38

AstraZeneca to Acquire Novexel 38

Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint

Venture 38

Pfizer and Aurobindo Pharma Ink Agreement for Producing Off

Patent Drugs 39

BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda 39

Novartis to Take Over Protez Pharmaceuticals 39

3i to Buy Alpharma Unit 40

NCPC to Acquire Stake in DSM's Antibiotics Division 40

ULL Establishes New Antibiotics Unit in Himachal Pradesh 40

Biocat to Expand Presence in the Indian Market 40

PRWT Acquires Cherokee Chemical Unit from Merck 40

CSPC Joins Hands with Indonesian Firms 41

9. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A

PERSPECTIVE BUILDER 42

Nisshin-Kyorin to Merge with Kyorin Pharmaceutical 42

Schering-Plough Acquires Organon BioSciences 42

GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and

Antivirals 42

Iroko Bags Canadian Rights to Vancocin® 43

Cubist Licenses CUBICIN Rights to Merck 43

Sagent Partners with Astral to Develop Injectable Antibiotics 43

MR Healthcare to Manufacture New Antibiotics & Medicines 43

Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo 44

C&O Pharmaceutical to Distribute Meiact in China 44

Bioton Signs Deal to Market Antibiotics in Russia 44

Toyama Gains Marketing Approval for Geninax® in Japan 44

Forest Laboratories Acquires Cerexa 44

Oscient Modifies Licensing Agreement With LG Life Sciences 44

Orchid Sign Licensing & Distribution Pact With Actavis 45

Forest Laboratories Revokes Partnership With Replidyne 45

SRI and Blanca Collaborate To Develop & Test Carbacephem 45

AstraZeneca To Expand Research Center For Antibiotics 45

Jade Pharmaceutical Begins Levofloxacin's Production in China 45

Reyoung To Start Antibiotic Production At New Facility 46

Toyama Begins T-705 Clinical Trials 46

SmPC For Sanofi-Aventis' Ketek® Updated 46

Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic

Tablets in France 46

Antibiotice Plans To Infuse Funds For Antibiotics Production 46

UAE Approves Pfizer's Zithromax SD 46

10. PRODUCT INNOVATIONS/INTRODUCTIONS 47

Janssen-Cilag Launches Doribax™ - New Carbapenem Antibiotic 47

MIT Scientists Develop a New Antibiotic, Rhodostreptomycin 47

Watson Pharma Introduces Biaxin XL's Generic Version 47

11. PRODUCT INNOVATIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER 48

Toyama Launches New Garenoxacin Quinolone Antibiotic 48

Wockhardt to Introduce Cefprozil in the US 48

MSD India Launches Invanza in India 48

Orchid Chemicals to Introduce Three New Drugs in the US 48

DUSA Pharmaceuticals Releases ClindaReach™ 49

Mylan Releases Cipro's Generic Version 49

Macrolide Antibiotic Developed In the US 49

University of Michigan Devises NMR Spectroscopy For Antibiotics 49

Glycopeptide-Cephalosporin Antibiotics Developed In The US 49

Neosil Tests NEO 101 Antibiotic 49

New Antibiotic Developed By Canadian Inventors 49

Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada 50

Penicillin Binding Protein Found In Japan 50

Venus Remedies Releases Mucomelt-Forte 50

12. FOCUS ON SELECT GLOBAL PLAYERS 51

Abbott Laboratories (USA) 51

Astellas Pharma, Inc. (Japan) 51

Bayer HealthCare AG (Germany) 51

Bristol-Myers Squibb Co. (USA) 52

Cubist Pharmaceuticals, Inc. (USA) 52

Daiichi Sankyo Company, Limited (Japan) 53

Eli Lilly and Co. (USA) 54

GlaxoSmithKline Plc (UK) 54

Johnson & Johnson (USA) 55

Kyorin Pharmaceutical Co., Ltd. (Japan) 55

LG Life Sciences Limited (Korea) 56

MiddleBrook™ Pharmaceuticals, Inc. (USA) 57

Novartis AG (Switzerland) 57

Pfizer Inc. (USA) 58

Pliva d.d. (Croatia) 59

Roche (Switzerland) 59

Sanofi-Aventis SA (France) 59

Takeda Pharmaceutical Company, Ltd. (Japan) 60

Toyama Chemical Co., Ltd. (Japan) 60

13. GLOBAL MARKET PERSPECTIVE 61

Table 9: World Recent Past, Current & Future Analysis for

Antibiotics by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 61

Table 10: World Historic Review for Antibiotics by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 62

Table 11: World 11-Year Perspective for Antibiotics by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 63

Table 12: World Recent Past, Current & Future Analysis for

Penicillin by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 64

Table 13: World Historic Review for Penicillin by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 65

Table 14: World 11-Year Perspective for Penicillin by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 66

Table 15: World Recent Past, Current & Future Analysis for

Cephalosporin by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 67

Table 16: World Historic Review for Cephalosporin by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), and Rest of World Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 68

Table 17: World 11-Year Perspective for Cephalosporin by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 69

Table 18: World Recent Past, Current & Future Analysis for

Macrolides by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 70

Table 19: World Historic Review for Macrolides by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 71

Table 20: World 11-Year Perspective for Macrolides by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 72

Table 21: World Recent Past, Current & Future Analysis for

Quinolones by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 73

Table 22: World Historic Review for Quinolones by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 74

Table 23: World 11-Year Perspective for Quinolones by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 75

Table 24: World Recent Past, Current & Future Analysis for

Carbapenems by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2007 through 2015 (includes corresponding Graph/Chart) 76

Table 25: World Historic Review for Carbapenems by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 77

Table 26: World 11-Year Perspective for Carbapenems by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 78

Table 27: World Recent Past, Current & Future Analysis for

Other Antibiotics by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 79

Table 28: World Historic Review for Other Antibiotics by

Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific

(excluding Japan), and Rest of World Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 80

Table 29: World 11-Year Perspective for Other Antibiotics by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Rest of World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 81

14. THE UNITED STATES 82

A. Market Analysis 82

Current and Future Analysis 82

Antibiotics Approved Between 2000 and 2005 in the United

States 82

Competition 83

Table 30: Leading Players in the US Antibiotics Market

(2008): Percentage Breakdown by Value Sales for Pfizer,

Johnson & Johnson, GlaxoSmithKline, Abbott, and Others

(includes corresponding Graph/Chart) 83

Key Players 83

B. Market Analytics 84

Table 31: US Recent Past, Current & Future Analysis for

Antibiotics by Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 84

Table 32: US Historic Review for Antibiotics by Product

Segment - Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 85

Table 33: US 11-Year Perspective for Antibiotics by Product

Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 86

15. CANADA 87

A. Market Analysis 87

Current And Future Analysis 87

B. Market Analytics 87

Table 34: Canadian Recent Past, Current & Future Analysis

for Antibiotics by Product Segment - Penicillin,

Cephalosporin, Macrolides, Quinolones, Carbapenems and Other

Antibiotics Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 87

Table 35: Canadian Historic Review for Antibiotics by

Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 88

Table 36: Canadian 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 89

16. JAPAN 90

A. Market Analysis 90

Current and Future Analysis 90

Key Players 90

B. Market Analytics 91

Table 37: Japanese Recent Past, Current & Future Analysis

for Antibiotics by Product Segment - Penicillin,

Cephalosporin, Macrolides, Quinolones, Carbapenems and Other

Antibiotics Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 91

Table 38: Japanese Historic Review for Antibiotics by

Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 92

Table 39: Japanese 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 93

17. EUROPE 94

A. Market Analysis 94

Current and Future Analysis 94

B. Market Analytics 95

Table 40: European Recent Past, Current & Future Analysis

for Antibiotics by Geographic Region - France, Germany,

Italy, UK, Spain, and Rest of Europe Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 95

Table 41: European Historic Review for Antibiotics by

Geographic Region - France, Germany, Italy, UK, Spain, and

Rest of Europe Markets Independently Analyzed with Annual

Sales in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 96

Table 42: European Recent Past, Current & Future Analysis

for Antibiotics by Product Segment - Penicillin,

Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other

Antibiotics Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 97

Table 43: European Historic Review for Antibiotics by

Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems, and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 98

Table 44: European 11-Year Perspective for Antibiotics by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, Italy, UK, Spain, and Rest of Europe

Markets for 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 99

Table 45: European 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems, and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 100

17a. FRANCE 101

A. Market Analysis 101

Current and Future Analysis 101

Trends 101

Over Consumption of Antibiotics - Cause of Concern 101

Sanofi-Aventis SA - A Key Player 101

B. Market Analytics 102

Table 46: French Recent Past, Current & Future Analysis for

Antibiotics by Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 102

Table 47: French Historic Review for Antibiotics by Product

Segment - Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 103

Table 48: French 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 104

17b. GERMANY 105

A. Market Analysis 105

Current and Future Analysis 105

Bayer HealthCare AG - A Key Player 105

B. Market Analytics 106

Table 49: German Recent Past, Current & Future Analysis for

Antibiotics by Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 106

Table 50: German Historic Review for Antibiotics by Product

Segment - Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 107

Table 51: German 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 108

17c. ITALY 109

A. Market Analysis 109

Current and Future Analysis 109

B. Market Analytics 109

Table 52: Italian Recent Past, Current & Future Analysis for

Antibiotics by Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 109

Table 53: Italian Historic Review for Antibiotics by Product

Segment - Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 110

Table 54: Italian 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 111

17d. THE UNITED KINGDOM 112

A. Market Analysis 112

Current And Future Analysis 112

GlaxoSmithKline Plc - A Key Player 112

B. Market Analytics 113

Table 55: UK Recent Past, Current & Future Analysis for

Antibiotics by Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 113

Table 56: UK Historic Review for Antibiotics by Product

Segment - Penicillin, Cephalosporin, acrolides, Quinolones,

Carbapenems and Other Antibiotics Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 114

Table 57: UK 11-Year Perspective for Antibiotics by Product

Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 115

17e. SPAIN 116

Market Analysis 116

Table 58: Spanish Recent Past, Current & Future Analysis for

Antibiotics by Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 116

Table 59: Spanish Historic Review for Antibiotics by Product

Segment - Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets Independently

Analyzed with Annual Sales in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 117

Table 60: Spanish 11-Year Perspective for Antibiotics by

Product Segment - Percentage Breakdown of Dollar Sales for

Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 118

17f. REST OF EUROPE 119

A. Market Analysis 119

Current and Future Analysis 119

Poland 119

Table 61: Polish Market for Antibiotics (2008): Percentage

Breakdown of Market Share by Leading Companies - GSK

Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes

corresponding Graph/Chart) 119

Focus On Select Players 119

B. Market Analytics 120

Table 62: Rest of Europe Recent Past, Current & Future

Analysis for Antibiotics by Product Segment - Penicillin,

Cephalosporin, Macrolides, Quinolones, Carbapenems and Other

Antibiotics Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 120

Table 63: Rest of Europe Historic Review for Antibiotics by

Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 121

Table 64: Rest of Europe 11-Year Perspective for Antibiotics

by Product Segment - Percentage Breakdown of Dollar Sales

for Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 122

18. ASIA-PACIFIC 123

A. Market Analysis 123

Current and Future Analysis 123

India 123

Rising Prices of Penicillin G to Affect Antibiotics Production 123

Market for Injectable Antibiotics Poised to Grow 123

Cipla, Pharmaceutical Market Leader in 2009 124

China 124

Carbapenem Witnesses Robust Growth in China 124

Key Players 125

Ranbaxy Laboratories Ltd. (India) 125

B. Market Analytics 126

Table 65: Asia-Pacific Recent Past, Current & Future

Analysis for Antibiotics by Product Segment - Penicillin,

Cephalosporin, Macrolides, Quinolones, Carbapenems and Other

Antibiotics Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 126

Table 66: Asia-Pacific Historic Review for Antibiotics by

Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 127

Table 67: Asia-Pacific 11-Year Perspective for Antibiotics

by Product Segment - Percentage Breakdown of Dollar Sales

for Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 128

19. REST OF WORLD 129

A. Market Analysis 129

Current and Future Analysis 129

B. Market Analytics 130

Table 68: Rest of World Recent Past, Current & Future

Analysis for Antibiotics by Product Segment - Penicillin,

Cephalosporin, Macrolides, Quinolones, Carbapenems and Other

Antibiotics Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 130

Table 69: Rest of World Historic Review for Antibiotics by

Product Segment - Penicillin, Cephalosporin,

Macrolides, Quinolones, Carbapenems and Other Antibiotics

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 131

Table 70: Rest of World 11-Year Perspective for Antibiotics

by Product Segment - Percentage Breakdown of Dollar Sales

for Penicillin, Cephalosporin, Macrolides, Quinolones,

Carbapenems and Other Antibiotics Markets for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 132

COMPETITION

Total Companies Profiled: 197 (including Divisions/Subsidiaries - 238)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 48

Canada 8

Japan 11

Europe 68

France 7

Germany 10

The United Kingdom 8

Italy 10

Spain 4

Rest of Europe 29

Asia-Pacific (Excluding Japan) 87

Middle East 11

Latin America 4

Africa 1

------------------------------------------

To order this report:Drug and Medication Industry: Global Antibiotics Industry

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Global Medical Specialty Bags Industry
2. Reportlinker Adds Global Ophthalmic Instrumentation Industry
3. Reportlinker Adds Global Nuclear Medicine Industry
4. Reportlinker Adds U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
5. Reportlinker Adds Proteomics - Technologies, Markets and Companies
6. Reportlinker Adds Cardiovascular Surgical Devices: The Global Market
7. Reportlinker Adds Neuroprotection - Drugs, Markets and Companies
8. Reportlinker Adds Toxicology and Pharmacology
9. Reportlinker Adds Virtual Pharma
10. Reportlinker Adds Quality for Biologics
11. Reportlinker Adds Endoscopy Devices Market Outlook in Belgium to 2016 - Endoscopy Visualization Systems, Flexible and Rigid Endoscopes, Capsule Endoscope Systems and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... VENICE, Fla. , Feb. 5, 2016 /PRNewswire/ ... Centers , is the first of its kind ... of undesired tattoos through advanced laser treatment. The ... Florida,s Suncoast by storm with ... video consultations, and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... 2016 --> ... "Fetal (Labor & Delivery) and Neonatal Care Equipment Market ... Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - ... studies the global market over the forecast period of ... 6.28 Billion in 2015 and is poised to grow ...
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ) ... "Global Obstetrics Partnering 2010-2016: Deal trends, players ... offering. --> Research and Markets ...
Breaking Medicine Technology:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... The answer may be at the tips of your toes. Foot massage, whether administered ... well as pure comfort and relaxation. The American Board of Multiple Specialties in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
Breaking Medicine News(10 mins):